usDiggRedditYahooMyWebGoogleFacebookWhat's this? Print Email Boomers on track to drive biotech The generation's health concerns are expected to propel medical advances By Lisa Rosetta The Salt Lake Tribune Article Launched:11/19/2007 12:12:17 AM MST By 1989, a boomer's median net worth was $36,000, according to Paul Root Wolpe, president of the American Society for Bioethics and Humanities. usDiggRedditYahooMyWebGoogleFacebookWhat's this? Print Email Boomers on track to drive biotech The...

Life expectancy has shot up by 178% in a century- Hindustan Times Welcome Guest Make HindustanTimes my homepage. When he heard that Britain's Queen Mother had died at 101, the News Corp chairman Rupert Murdoch is reported to have responded, "An early death!" The diet and exercise conscious septuagenarian plans to be on the topside of the experts who say that the average Australian will live to be 100 by 2050. When he heard that Britain's Queen Mother had died at 101, the News Corp chairman...

As assessed by independent radiological review, 36 percent (31/85) of GBM patients treated with Avastin alone, and 51 percent (42/82) of patients treated with Avastin in combination with chemotherapy, lived without the disease advancing within six months. Study Results In addition to six-month PFS rates of 36 and 51 percent respectively in the Avastin-alone and Avastin plus chemotherapy arms, preliminary estimates of tumor response were observed in 21 percent (18/85) of patients treated...

An executive report on the emerging companies, government incentives and recent investments that are defining China's burgeoning biotech industry. An executive report on the emerging companies, government incentives and recent investments that are defining China's burgeoning biotech industry. This report provides an in-depth review of the biotech industry mix (service provider, innovators and biogenerics companies), provides an analysis of the Chinese government's role in biotech, and...

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced...

Scientists there say they have successfully cloned the world's first monkey embryos, deriving stem cells for medical research but potentially paving the way for the cloning of human embryos, as well. MORRONE: It doesn't seem to be, according to the technology that we've had to this point, possible, but without taking it forward and looking at can we get stem cells without destroying embryos? Can we work with blastocysts, which is a funny name for, you know, something that is growing a...

TORONTO, April 12 /CNW/ - ARIUS Research inc. (TSX-VE: ARI) announcedtoday that it will present data on therapeutic anti-cancer antibody programsgenerated from its FunctionFIRST(TM) platform, and results from its researchcollaboration with Oxford BioMedica (LSE: OXB) at the 96th Annual Meeting ofthe American Association for Cancer Research in Anaheim/Orange County, CA fromApril 16-20, 2005. TORONTO, April 12 /CNW/ - ARIUS Research inc. (TSX-VE: ARI) announcedtoday that it will present data...

Simon Yarrow says while the bio-polymer components are off the shelf ingredients, it is the intellectual property and research ability the company has that put it in a niche of its own. EnCoate is building on its original technology for bio-insecticides that uses bio-polymers to encase the naturally occurring bacteria that kills grass grub. However Simon Yarrow says the company is within a year of offering an encapsulated pro-biotic ingredient suitable for dry products like energy bars or...

TOKYO (Thomson Financial) - Sixteen major Japanese firms including Nippon Oil Corp, (Nachrichten) Toyota Motor Corp and Mitsubishi Heavy Industries Ltd plan to develop technology to mass-produce low-cost bioethanol fuel from rice hulls and used construction materials in cooperation with universities and government agencies, the Nikkei reported on Sunday without citing sources. TOKYO (Thomson Financial) - Sixteen major Japanese firms including Nippon Oil Corp, (Nachrichten) Toyota Motor...